openPR Logo
Press release

Advancing Pharmaceutical Analysis with Bedaquiline Impurity Standards: Aquigen Bio's Comprehensive Portfolio

06-23-2025 09:31 AM CET | Chemicals & Materials

Press release from: Aquigen Bio Sciences

Advancing Pharmaceutical Analysis with Bedaquiline Impurity

In the dynamic landscape of pharmaceutical development, impurity profiling plays a pivotal role in ensuring drug safety, efficacy, and regulatory compliance. With rising regulatory scrutiny and evolving analytical methodologies, the need for high-purity impurity standards has never been greater-especially for critical anti-tuberculosis drugs like Bedaquiline.

At Aquigen Bio, our dedication to analytical integrity and pharmaceutical innovation has led to the development of a comprehensive suite of Bedaquiline impurity standards. These compounds are tailored to meet the needs of quality control labs, formulation scientists, and regulatory experts involved in the development, validation, and manufacturing of Bedaquiline-based formulations.
In this blog, we'll explore the importance of Bedaquiline impurity standards, the challenges associated with impurity identification, and how Aquigen Bio's specialized reference materials-like Bedaquiline Impurity 6 and Bedaquiline D6-are facilitating progress across the pharmaceutical industry.

Understanding Bedaquiline: A Breakthrough in TB Therapy
Bedaquiline is a diarylquinoline antimycobacterial drug primarily used for the treatment of multidrug-resistant tuberculosis (MDR-TB). Approved by the USFDA and WHO, it represents a significant leap in global TB management due to its unique mechanism-targeting ATP synthase in Mycobacterium tuberculosis.
However, like any API (Active Pharmaceutical Ingredient), the manufacturing and degradation pathways of Bedaquiline can lead to the formation of impurities. These impurities-whether process-related, degradation products, or synthetic byproducts-must be identified, quantified, and controlled within acceptable regulatory limits.

Why Bedaquiline Impurity Standards Are Crucial
Impurities in pharmaceutical substances may compromise drug safety and therapeutic performance. Global regulatory bodies like the ICH, USFDA, and EMA mandate thorough impurity profiling for both new and generic drug applications.

For Bedaquiline, specific impurities must be monitored at trace levels due to potential safety concerns, including genotoxicity or reduced efficacy. This is where certified impurity standards come into play-they are essential for:
Analytical method development and validation

Impurity quantification and threshold identification

Stability testing under various stress conditions

Regulatory filings (ANDA, DMF, etc.)

Aquigen Bio provides a diverse collection of Bedaquiline impurity standards that empower laboratories to meet these stringent requirements with confidence.

Aquigen Bio's Bedaquiline Impurity Portfolio

We offer an expanding range of impurity reference materials designed specifically for Bedaquiline-related analysis. Each compound is synthesized under strict quality controls and is supplied with a comprehensive Certificate of Analysis (CoA), including NMR, MS, and HPLC purity data.
Let's explore some of our most in-demand Bedaquiline impurities:

1. Bedaquiline Impurity 6
https://aquigenbio.com/product/bedaquiline-impurity-6/

Bedaquiline Impurity 6 is a vital analytical standard used for routine monitoring of side-products in the Bedaquiline synthesis process. It is highly useful during:
Stress testing of formulations

Identification of synthetic route deviations

Evaluation of impurity fate during shelf-life studies

This impurity is isolated and characterized with a purity level exceeding 98%, ensuring consistent analytical performance across laboratories.

2. Bedaquiline D6

https://aquigenbio.com/product/bedaquiline-d6/
The Bedaquiline D6 compound is a deuterated internal standard used extensively in LC-MS/MS applications. By replacing hydrogen atoms with deuterium, Bedaquiline D6 provides:
Enhanced signal clarity

Better detection limits for Bedaquiline quantification

Greater reproducibility in bioanalytical assays

Pharmacokinetic and bioequivalence studies particularly benefit from the use of this stable isotope-labeled standard, making it indispensable for clinical research organizations and pharmaceutical sponsors alike.

3. Bedaquiline Nitroso Impurity 2
https://aquigenbio.com/product/bedaquiline-nitroso-impurity-2/

Nitrosamine impurities are under intense scrutiny globally due to their potential genotoxic and carcinogenic properties. Bedaquiline Nitroso Impurity 2 is developed specifically to assist in:
Nitrosamine risk assessment

Quantification under ICH M7 guidelines

LC-MS method validation at ppb (parts per billion) levels

With the increasing regulatory focus on nitrosamines, this impurity standard is vital for ensuring compliance and patient safety.

4. Bedaquiline Des-Bromo Diastereomer Impurity 1
https://aquigenbio.com/product/bedaquiline-des-bromo-diastereomer-impurity-1/

This impurity arises due to minor alterations in stereochemistry and halogen substitution during synthesis. It helps in:
Identifying chiral purity deviations

Supporting stereoselective synthesis validations

Providing reference for stability-indicating method development

Diastereomeric impurities are often difficult to detect without highly specific reference standards, making Aquigen Bio's offering invaluable for comprehensive Bedaquiline analysis.

Use Cases: Who Needs These Impurity Standards?
Aquigen Bio's Bedaquiline impurity standards are ideal for:
Generic manufacturers filing ANDAs or DMFs

CROs and CDMOs conducting method validation

QC labs performing routine impurity analysis

Regulatory bodies involved in dossier evaluation

Academic researchers in analytical chemistry and pharmacology

With global shipping and rapid delivery, Aquigen Bio ensures that critical reference materials reach your lab on time, wherever you are in the world.

Aquigen Bio Sciences
281/1, Plot No 41,
Hinjawadi - Pirangut Rd,
Kasar Amboli, Pirangut,
Pune, Maharashtra 412108
Visit: www.aquigenbio.com

Aquigen Bio Sciences stands as India's premier resource for high-quality N-Nitroso impurity standards, impelling advancements in pharmaceutical research and manufacturing. Specializing in providing precise impurity standards - including degradation impurities, process impurities, and deuterated isotopes - Aquigen Bio Sciences empowers the industry to comply with the most rigorous global regulations. The contract research organization's commitment to precision and reliability makes it the trusted partner for addressing complex issues like N-Nitroso impurities in pharmaceuticals.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Advancing Pharmaceutical Analysis with Bedaquiline Impurity Standards: Aquigen Bio's Comprehensive Portfolio here

News-ID: 4076835 • Views:

More Releases from Aquigen Bio Sciences

Aquigen Bio Launches High-Purity Impurity Standards for Pizotifen, Padimate-O & Pacritinib
Aquigen Bio Launches High-Purity Impurity Standards for Pizotifen, Padimate-O & …
Aquigen Bio, a trusted provider of pharmaceutical reference standards and research tools, is pleased to announce the launch of new impurity standards for three critical pharmaceutical and cosmeceutical compounds: Pizotifen, Padimate-O, and Pacritinib. As the pharmaceutical and personal care industries face growing regulatory scrutiny and an increasing demand for analytical precision, Aquigen Bio continues to deliver certified reference materials (CRMs) that empower laboratories to meet quality benchmarks and support safe, compliant
Advancing Pharmaceutical Precision with Remifentanil EP Impurity L from Aquigen Bio
Advancing Pharmaceutical Precision with Remifentanil EP Impurity L from Aquigen …
In the high-stakes world of pharmaceutical manufacturing, precision, purity, and compliance are non-negotiable. Regulatory frameworks like the European Pharmacopoeia (EP) set clear expectations for drug safety and efficacy, with stringent requirements for impurity profiling. Remifentanil EP Impurity L-now available from Aquigen Bio-is a key standard developed to help drug developers and quality control teams meet these critical demands. Click link to know more about Remifentanil EP Impurity L https://aquigenbio.com/product/remifentanil-ep-impurity-l/ This impurity, specified in
Elevating Pharmaceutical Quality with Aquigen Bio's Premium Impurity Standards for Butylhydroxyanisole, and Butorphanol
Elevating Pharmaceutical Quality with Aquigen Bio's Premium Impurity Standards f …
June 2025 - In a mission to support global pharmaceutical compliance and analytical precision, Aquigen Bio has expanded its impurity standards portfolio with high-quality, certified reference materials (CRMs) for Butylhydroxyanisole, and Butorphanol. These specialized impurity standards are crucial for accurate testing, regulatory submissions, and ensuring the safety and efficacy of drug formulations. Know more about Butorphanol :https://aquigenbio.com/product/butorphanol/ Ensuring Purity with Butylhydroxyanisole Impurity Standards Butylhydroxyanisole (BHA), widely used as an antioxidant in pharmaceutical formulations,
Aquigen Bio Launches High‐Purity Omadacycline Impurity 6: Catalyzing Next‐Gen Antibiotic Research
Aquigen Bio Launches High‐Purity Omadacycline Impurity 6: Catalyzing Next‐Ge …
Aquigen Bio, a trusted leader in fine chemical standards and biotech reagents, officially announces the availability of Omadacycline Impurity 6. This milestone enables researchers and pharmaceutical partners to advance studies on omadacycline-an FDA‐approved, next‐generation tetracycline antibiotic-by characterizing degradation pathways, ensuring drug quality, and bolstering regulatory robustness. Why Omadacycline Impurity 6 Matters https://aquigenbio.com/product/omadacycline-impurity-6/ Omadacycline has rapidly emerged as a powerful antibiotic treatment for complicated skin infections and community‐acquired bacterial pneumonia. Like all small‐molecule drugs,

All 5 Releases


More Releases for Bedaquiline

Healthcare Contract Research Organization Market Size, Share Estimation and Fore …
Global Healthcare Contract Research Organization Market to reach USD 64 billion by 2027.Global Healthcare Contract Research Organization Market is valued at approximately USD 40.9 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 6.6 % over the forecast period 2021-2027. The U.S. current-account deficit increased and reached US$ 234.8 billion in Q4 2021. However, the Canadian Dollar exchange (CAD) increased by 29.9% in
Tuberculosis Market Analysis: Insights into Novel and Emerging Pipeline Therapie …
(Albany, US) DelveInsight's "Tuberculosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Tuberculosis, historical and forecasted epidemiology as well as the Tuberculosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Click here to know more about Tuberculosis Market report offerings: https://www.delveinsight.com/report-store/tuberculosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr Some of the key facts of the Tuberculosis Market Report: 1. Tuberculosis is caused by a group of closely
Global Tuberculosis Drugs Market Top Leading Players with Strategies and Forecas …
The global tuberculosis drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is anticipated to augment the market during the forecast period includes an increase in R&D investments and an increase in new drug developments. For instance, a US-based TB Alliance, which is a non-profit organization, has developed a new drug for treating highly drug-resistant forms of tuberculosis. The TB
Anti-tuberculosis Therapeutics Market Analysis Report 2021-2027| Isoniazid, Rifa …
High incidence of drug-sensitive (DS) tuberculosis (TB), increasing cases of multidrug-resistant (MDR) tuberculosis, and increasing R&D efforts for drug development are some of the factors that are expected to propel the anti-tuberculosis therapeutics market growth. Anti-tuberculosis Therapeutics Market report is a comprehensive analysis of the global market has newly added by A2Z Market Research to its extensive repository. The statistical report offers a prime wellspring of applicable information for global business
Tuberculosis Drugs Market Share 2021 Future Trends, Manufacturers, Share, Opport …
Market Intelligence Data has released a new report on the global “Tuberculosis Drugs market”. The document gives a complete evaluation of the market. It understands market development through in-depth insights, tracking historical results and analysing current scenarios and future forecasts based on optimistic and possible situations. The report provides detailed statistics on the Tuberculosis Drugs market industry and its framework. The Global Tuberculosis Drugs Market Size is Projected to Reach at
Tuberculosis Drugs Market Trends 2021, In-Depth Analysis of Industry Growth and …
The global Tuberculosis Drugs Market size is expected to reach USD 1.38 billion by 2027, registering a CAGR of 5.2% during the forecast period. The tuberculosis drug industry is growing with an increasing number of drug breakthroughs. The US-based TB Alliance has created a new medicine for the treatment of tuberculosis, which is highly drug-resistants. TB Alliance, for example, was approved for Pretomnid in August 2019 by the U.S. FDA, a